Duke Robotics starts Nasdaq trading, DUKR slides under deal price

May 22, 2026
Duke Robotics starts Nasdaq trading, DUKR slides under deal price

New York, May 22, 2026, 17:03 EDT

  • DUKR changed hands at $7.02 on Friday, slipping under the $8.20 price set in last week’s Nasdaq-linked sale.
  • Duke Robotics raised roughly $9.2 million and shifted its common stock and warrants over to the Nasdaq Capital Market.
  • The company posted a net loss of $921,000 in the first quarter and reported no revenue. The update shifted attention to execution instead of earnings.

Duke Robotics Corp. was last at $7.02 Friday in early Nasdaq trading, falling under its recent $8.20 offering price. The drone maker’s shares moved between $6.80 and $7.23, according to Investing.com. Investors are looking at new funding while the company’s short-term numbers stay slim.

DUKR is in the early stage of trading on Nasdaq. Duke finished a $9.2 million underwritten public offering on May 18, selling 1,125,000 units that each included a common share and a warrant—letting investors buy a share down the line at a fixed price. Both the stock and warrants started to trade on Nasdaq on May 15 under the tickers DUKR and DUKRW.

Duke’s Q1 numbers show no revenue, with the company posting a $513,000 operating loss and a net loss of $921,000, or 41 cents per share. As of March 31, cash and restricted cash totaled $510,000, ahead of the May offering.

Duke CEO Yossef Balucka said this quarter put the company at a “clear inflection point.” Balucka pointed to three platforms: the Insulator Cleaning Drone, or IC Drone, which targets high-voltage utility gear; AEROTRACE, an aerial monitoring tool using AI; and Bird of Prey, a stabilized weaponized drone system sold with Elbit Systems Land. GlobeNewswire

Duke said its March PO from Israel Electric Corporation should bring in over $1 million revenue for 2026. The company added that first quarter IC Drone service revenue is usually missing since the cleaning season tends to kick off in Q2.

Duke now has more flexibility to work on turning orders into sales after the offering. The company said it will use the net proceeds for research and development, hiring more sales staff, marketing, business development, possible acquisitions and working capital.

Duke has moved into a busy segment of the defense and infrastructure business. Red Cat Holdings and AeroVironment, which have better-known drone operations, said they are working together to deploy Red Cat’s FANG first-person-view drones from AeroVironment’s P550 unmanned system. That points to how investors have a range of drone-defense plays in the public market.

Stocks climbed Friday. The Nasdaq Composite added 0.2%, the S&P 500 gained 0.4%, and the Russell 2000 rose 0.9%, AP reported. U.S. equity markets kept normal hours before closing for Memorial Day on Monday.

The downside is hard to ignore. Duke still has to show its utility-drone business can get past early sales, that defense contracts will actually bring in revenue, and that new warrants or capital raises won’t hurt holders by diluting their stakes — dilution meaning investors end up with less of the company if more shares get issued.

Next week’s test isn’t just about a single trading session. The question is if the new Nasdaq listing delivers steady liquidity. Right now, DUKR trades like an early drone play with new funds, Nasdaq exposure, and little room for execution mistakes.

Stock Market Today

  • Pro Medicus (PME) Share Price and Healthcare Sector Appeal on ASX
    May 22, 2026, 6:56 PM EDT. The Pro Medicus Ltd (ASX:PME) share price has dropped 42.5% since early 2025, prompting investor interest in healthcare stocks. Pro Medicus offers radiology IT software, including its flagship Visage platform that enables remote access to medical imaging, improving diagnostics. The S&P/ASX200 Healthcare Index has underperformed the broader market over five years but remains attractive due to three factors: stable, 'sticky' revenue streams unaffected by economic cycles; strong growth prospects, especially in healthcare IT and SaaS with projected 15%+ annual revenue growth; and rising ethical investing trends favoring essential healthcare services. PME trades at a price-to-sales ratio of 82.77x, slightly above its 5-year average, reflecting valuation considerations amid recent share price changes.